Conjugate vaccines--a breakthrough in vaccine development

Area of Science:

• Bacteriology
• Immunology
• Vaccinology

Background:

• Encapsulated bacteria like Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b (Hib) are primary causes of purulent meningitis in infants.
• The bacterial polysaccharide capsule is crucial for virulence, and antibodies against it offer protection.
• Infants cannot produce antibodies to polysaccharides, rendering traditional polysaccharide vaccines ineffective in early life.

Purpose of the Study:

• To explore the development and efficacy of conjugate vaccines for preventing bacterial meningitis in infants.
• To highlight the success of protein-conjugated polysaccharide vaccines in overcoming infant immune unresponsiveness.

Main Methods:

• Development of conjugate vaccines by linking bacterial polysaccharides to protein carriers.
• Clinical trials and national immunization program data analysis for Hib, meningococcal, and pneumococcal conjugate vaccines.

Main Results:

• The Haemophilus influenzae type b (Hib) conjugate vaccine, introduced in 1987, successfully induced antibody production and protection in infants, leading to the near elimination of Hib disease.
• Group C meningococcal and 7-valent pneumococcal conjugate vaccines, available since 2000, demonstrate high efficacy in preventing bacteremic diseases.
• Conjugate vaccines elicit immunologic memory and reduce asymptomatic bacterial carriage, contributing to significant herd immunity.

Conclusions:

• Protein-conjugate technology has revolutionized infant immunization strategies against encapsulated bacterial pathogens.
• Conjugate vaccines are highly effective in preventing severe diseases like meningitis and bacteremia and confer broad public health benefits through herd immunity.